Temporary parallel export ban issued to ensure continued supply of medicines

Temporary parallel export ban issued to ensure continued supply of medicines

October 3, 2019

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have issued a list of medicines which must not be parallel exported from the UK. This action has been taken to ensure the continued supply of medicines to meet the needs of UK patients.

DHSC and the MHRA have written to medicine manufacturers and wholesalers to remind them of their responsibilities to ensure the continued supply of medicines to meet the needs of UK patients. The letter also includes the list of medicinal products which “cannot be supplied for parallel export or parallel distribution from the UK or hoarded (held back)” for the time being.

The list, which will be reviewed on an ongoing basis, contains any product that meets the following criteria:

  1. the medicine is required to meet the needs of UK patients;
  2. the medicine is either being parallel exported or is at threat of being parallel exported; and
  3. the export of that medicine is either contributing to, or may contribute to, a shortage of that medicine in the UK.

The list currently includes products such as Adrenaline auto-injectors, Estradiol, Hepatitis B (rDNA) suspension for injection, Levonorgestrel and Progesterone.

Read the DHSC/MHRA letter to holders of a wholesale dealer licence

View the list of medicines that cannot be parallel exported from the UK (as of 3rd October)

Any manufacturer or wholesaler found parallel exporting one or more of these medicines could face the immediate suspension of their wholesaler dealer licence.



Posted in: ,


More Latest News >